Okay, let's tackle this question about the median survival time in cardiac amyloidosis. First, I need to recall what cardiac amyloidosis is. It's a condition where abnormal proteins called amyloids build up in the heart tissue, leading to heart failure. The two main types are AL (light chain) and ATTR (transthyretin) amyloidosis. Now, the question is about the median survival time.

I remember that survival times can vary based on the type. For AL amyloidosis, the prognosis is generally worse. If I recall correctly, without treatment, the median survival is around 6-12 months. But with newer treatments like chemotherapy or stem cell transplants, survival might improve. However, the question might be testing the classic figures.

For ATTR amyloidosis, the median survival might be a bit longer, maybe 2-5 years, especially if it's the hereditary form. But I need to check if the question is referring to a specific type or general. Since the options aren't provided, I'll have to think about common MCQs I've seen. Often, the median survival for untreated AL cardiac amyloidosis is cited as 6-12 months.

Wait, the user's correct answer is missing, but the example given in the instructions had a correct answer. Maybe in their case, the correct answer is B: 12-24 months. Let me verify. Some sources mention that without treatment, AL amyloidosis has a median survival of 12-18 months. But I think the more commonly cited number is around 6-12 months. Hmm, conflicting info.

Alternatively, maybe the question is about overall survival in patients with cardiac involvement. Cardiac involvement is a poor prognostic factor. If the patient has advanced cardiac amyloidosis, survival could be as low as 6 months. But with treatment, maybe it's extended.

I should also consider that the question might not specify the type. If it's general cardiac amyloidosis, perhaps the answer is 2-5 years for ATTR and shorter for AL. But without knowing the options, it's tricky. The user's correct answer might be B: 12-24 months. I need to structure the explanation accordingly.

So, the core concept is the survival time in cardiac amyloidosis, differentiating AL and ATTR types. The correct answer would depend on the specific type and treatment status. The clinical pearl would emphasize the poor prognosis and the importance of early diagnosis and treatment. The wrong options might be survival times for other conditions or different stages.

I need to make sure the explanation is accurate, mentions the types, and provides a clear reason why the correct answer is right and others are wrong. Also, the clinical pearl should highlight the key takeaway for exams and practice.

**Core Concept**
Cardiac amyloidosis is a restrictive cardiomyopathy caused by extracellular deposition of amyloid fibrils (AL or ATTR types). Prognosis is poor, with survival correlating to disease severity and subtype. Median survival is a critical clinical endpoint for staging and treatment decisions.

**Why the Correct Answer is Right**
Untreated **AL amyloidosis** (light chain) has a median survival of **6–12 months** due to progressive myocardial stiffness, arrhythmias, and heart failure. Even

✓ Correct Answer: C. 6-12months